| |
Mesalamine
|
Immunomodulator monotherapy
|
Biologic monotherapy
|
Combination therapy
|
Systemic steroids
|
|---|
|
No therapy
|
|
Females
|
− 3.4 (− 3.9, − 2.9)
|
3.2 (2.4, 4.1)
|
2.3 (0.4, 4.2)
|
− 1.8 (− 4.5, 0.9)
|
7.1 (6.3, 7.8)
|
|
Males
|
− 2.5 (− 3.0, − 2.1)
|
3.3 (2.5, 4.0)
|
2.5 (0.7, 4.3)
|
0.4 (− 2.2, 3.1)
|
6.8 (6.2, 7.5)
|
|
Mesalamine
|
|
Females
| |
6.7 (5.8, 7.5)
|
5.7 (3.8, 7.6)
|
1.6 (− 1.1, 4.3)
|
10.5 (9.7, 11.3)
|
|
Males
| |
5.8 (5.0, 6.6)
|
5.0 (3.2, 6.8)
|
3.0 (0.3, 5.6)
|
9.4 (8.7, 10.0)
|
|
Immunomodulator monotherapy
|
|
Females
| | |
− 0.9 (− 3.0, 1.1)
|
− 5.1 (− 7.8, − 2.3)
|
3.8 (2.8, 4.9)
|
|
Males
| | |
− 0.8 (− 2.7, 1.1)
|
− 2.8 (− 5.5, − 0.1)
|
3.6 (2.7, 4.5)
|
|
Biologic monotherapy
|
|
Females
| | | |
− 4.1 (− 7.4, − 0.9)
|
4.8 (2.8, 6.7)
|
|
Males
| | | |
− 2.1 (− 5.2, 1.1)
|
4.3 (2.5, 6.2)
|
|
Combination therapy
|
|
Females
| | | | |
8.9 (6.1, 11.6)
|
|
Males
| | | | |
6.4 (3.7, 9.1)
|
- Differences correspond to the medication referenced in the column name subtracted from the medication reference in the row name (i.e., LErow – LEcolumn). Significant differences are indicated in bold font
